1-15 of 22
Expanding Treatment Options in PNH: Expert Approaches to Personalized Care
Medical Industry FeatureExpanding Treatment Options in PNH: Expert Approaches to Personalized Care
Caroline Piatek, MD
Bhumika Patel, MD
Long-Term PNH Management: Addressing Treatment Goals Beyond Symptom Control
Medical Industry FeatureLong-Term PNH Management: Addressing Treatment Goals Beyond Symptom Control
Arati Chand, MD
Bhumika Patel, MD
Understanding the Mechanism Behind a Treatment Approach in Indolent Systemic Mastocytosis (ISM)
Medical Industry FeatureUnderstanding the Mechanism Behind a Treatment Approach in Indolent Systemic Mastocytosis (ISM)
On the Frontline: Empowering IO Therapies for Patients with HER2-Negative G/GEJC
Project Oncology®On the Frontline: Empowering IO Therapies for Patients with HER2-Negative G/GEJC
Charles Turck, PharmD, BCPS, BCCCP
Jun Gong, MD
Evaluating EFS and Surgical Outcomes in Resectable NSCLC: Insights From a Clinical Trial
Medical Industry FeatureEvaluating EFS and Surgical Outcomes in Resectable NSCLC: Insights From a Clinical Trial
Early CAR T Cell Therapy Referral: The Missing Piece in Blood Cancer Treatment
Project Oncology®Early CAR T Cell Therapy Referral: The Missing Piece in Blood Cancer Treatment
- advertisement
Rewiring Your Thinking in Paroxysmal Nocturnal Hemoglobinuria
Medical Industry FeatureRewiring Your Thinking in Paroxysmal Nocturnal Hemoglobinuria
Steve Stone, PA-C
George Yaghmour, MD
Moving Beyond Hesitation: Exploring an Oral Option for Managing PNH
Medical Industry FeatureMoving Beyond Hesitation: Exploring an Oral Option for Managing PNH
Steve Stone, PA-C
Jamile Shammo, MD, FASCP, FACP
Personalizing PNH Care: Exploring the Role of Iptacopan in Clinical Practice
Medical Industry FeaturePersonalizing PNH Care: Exploring the Role of Iptacopan in Clinical Practice
Steve Stone, PA-C
Srinivasa Sanikommu, MD
Ibrahim Aldoss, MD
Harnessing the Immune Power: A Uniquely Designed PD-1 Inhibitor for Esophageal Cancer
Project Oncology®Harnessing the Immune Power: A Uniquely Designed PD-1 Inhibitor for Esophageal Cancer
Charles Turck, PharmD, BCPS, BCCCP
Jaffer Ajani, MD
Latest TROP2 ADC Approval for HR+ HER2- Metastatic Breast Cancer
Medical Industry FeatureLatest TROP2 ADC Approval for HR+ HER2- Metastatic Breast Cancer
Charles Turck, PharmD, BCPS, BCCCP
Komal Jhaveri, MD, FACP
Vanessa Soto-Romano
- advertisement
Managing Eye-Related Adverse Events Caused by Cancer Treatments
Medical Industry FeatureManaging Eye-Related Adverse Events Caused by Cancer Treatments
Neel D. Pasricha, MD
MIRASOL Insights in PROC: A Biomarker-Driven Approach
Project Oncology®MIRASOL Insights in PROC: A Biomarker-Driven Approach
Charles Turck, PharmD, BCPS, BCCCP
Cecelia Boardman, MD
Operational Considerations for Bispecific T-Cell Engager Therapies
Medical Industry FeatureOperational Considerations for Bispecific T-Cell Engager Therapies
Jennifer Caudle, DO, FACOFP
David M. Waterhouse, MD, MPH
